Previous close | 5.24 |
Open | 5.31 |
Bid | 5.30 x 1000 |
Ask | 5.50 x 3000 |
Day's range | 5.28 - 5.54 |
52-week range | 3.10 - 7.77 |
Volume | |
Avg. volume | 3,542,483 |
Market cap | 1.198B |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.59 |
Earnings date | 27 Oct 2022 - 31 Oct 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.86 |
WALTHAM, Mass., August 01, 2022--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
With me today are Mark Enyedy, our president and CEO; Anna Berkenblit, our chief medical officer; Kristen Harrington-Smith, our chief commercial officer; and Susan Altschuller, our CFO. During today's call, we will review recent accomplishments for the business, our Q2 financial results, and highlight upcoming anticipated events.